Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elite PharmaceuticalsELTP -2.33%60 3-Year EPS without NRI Growth Rate is 102.70% as of Jun. 2026, which is 378% above its 10-year median of 21.50. GuruFocus rates ELTP with a GF Score™ of 60/100 and a GF Value™ of $0.52 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 782 Drug Manufacturers companies, Elite Pharmaceuticals ranks better than 97.7% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 102.70% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 58.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Elite Pharmaceuticals was 125.70% per year. The lowest was -98.10% per year. And the median was 21.50% per year.
Elite Pharmaceuticals (OTCPK:ELTP) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Elite Pharmaceuticals 3-Year EPS without NRI Growth Rate Related Terms
ELTP vs EBS, ANIK, AKBA: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elite Pharmaceuticals 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Elite Pharmaceuticals's 3-Year EPS without NRI Growth Rate falls into.
Elite Pharmaceuticals 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 102.70% mean?
Elite Pharmaceuticals (ELTP) has a 3-Year EPS without NRI Growth Rate of 102.70% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Elite Pharmaceuticals and its competitors. This is 378% above median its historical median of 21.50. According to the industry distribution chart, Elite Pharmaceuticals ranks #18 out of 782 companies in the Drug Manufacturers industry, placing it in the top 2.3%.
Is Elite Pharmaceuticals' 3-Year EPS without NRI Growth Rate too high?
Elite Pharmaceuticals' current 3-Year EPS without NRI Growth Rate of 102.70% is 378% above median its 10-year median of 21.50. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.80. Elite Pharmaceuticals' value of 102.70% is 948% above this industry median. Based on the distribution chart, Elite Pharmaceuticals ranks #18 out of 782 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Elite Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' 3-Year EPS without NRI Growth Rate compare to EBS and ANIK?
According to the Drug Manufacturers industry distribution chart, Elite Pharmaceuticals ranks #18 out of 782 companies for 3-Year EPS without NRI Growth Rate. This places Elite Pharmaceuticals in the top 2% of its industry — outperforming the majority of peers. The industry median 3-Year EPS without NRI Growth Rate is 9.80. Elite Pharmaceuticals' value of 102.70% is 948% above this benchmark. While the company's 10-year median is 21.50 vs. the industry median of 9.80, Elite Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.80, based on 782 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elite Pharmaceuticals's current 3-Year EPS without NRI Growth Rate of 102.70% is 948% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Elite Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elite Pharmaceuticals's current 3-Year EPS without NRI Growth Rate is 102.70%, which is 378% above median its own 10-year median of 21.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.52, compared to a current price of $0.25 — trading 51.7% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 102.70%, which is 378% above median its 10-year median of 21.50 and 948% above the Drug Manufacturers industry median of 9.80. Elite Pharmaceuticals' overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current 3-Year EPS without NRI Growth Rate is 102.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?
Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued.
The current stock price of $0.25 is trading 51.7% below its estimated GF Value™ of $0.52.
GuruFocus considers Elite Pharmaceuticals to be Significantly Undervalued.
Key valuation signals for ELTP:
3-Year EPS without NRI Growth Rate: 102.70% (378% above median its 10-year median of 21.50)
GF Value™: $0.52 vs. price of $0.25 (51.7% below fair value)
Industry Position: 948% above the Drug Manufacturers median (#18 of 782)
No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
60GF Score
Get the complete analysis for ELTP
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELTP has been successfully added to your 
